Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney diseaseResearch in context

Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney diseaseResearch in context

Background: Senescent cells, which can release factors that cause inflammation and dysfunction, the senescence-associated secretory phenotype (SASP), accumulate with ageing and at etiological sites in multiple chronic diseases. Senolytics, including the combination of Dasatinib and Quercetin (D + Q)...

Full description

Bibliographic Details
Main Authors: LaTonya J. Hickson, Larissa G.P. Langhi Prata, Shane A. Bobart, Tamara K. Evans, Nino Giorgadze, Shahrukh K. Hashmi, Sandra M. Herrmann, Michael D. Jensen, Qingyi Jia, Kyra L. Jordan, Todd A. Kellogg, Sundeep Khosla, Daniel M. Koerber, Anthony B. Lagnado, Donna K. Lawson, Nathan K. LeBrasseur, Lilach O. Lerman, Kathleen M. McDonald, Travis J. McKenzie, João F. Passos, Robert J. Pignolo, Tamar Pirtskhalava, Ishran M. Saadiq, Kalli K. Schaefer, Stephen C. Textor, Stella G. Victorelli, Tammie L. Volkman, Ailing Xue, Mark A. Wentworth, Erin O. Wissler Gerdes, Yi Zhu, Tamara Tchkonia, James L. Kirkland
Format: Article
Language:English
Published: Elsevier 2019-09-01
Series:EBioMedicine
Online Access:http://www.sciencedirect.com/science/article/pii/S2352396419305912

Internet

http://www.sciencedirect.com/science/article/pii/S2352396419305912

Similar Items